Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 8(60), p. 5047-5050, 2016

DOI: 10.1128/aac.00168-16

Links

Tools

Export citation

Search in Google Scholar

Modeling Meropenem Treatment, Alone and in Combination with Daptomycin, for KPC-Producing Klebsiella pneumoniae Strains with Unusually Low Carbapenem MICs

Journal article published in 2016 by P. Gagetti, F. Pasteran, M. P. Martinez ORCID, M. Fatouraei, J. Gu, R. Fernandez, L. Paz, W. E. Rose, A. Corso, A. E. Rosato
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT Klebsiella pneumoniae strains producing K. pneumoniae carbapenemase (KPC) cause serious infections in debilitated and immunocompromised patients and are associated with prolonged hospital stays and increased mortality rates. Daptomycin is a lipopeptide used against Staphylococcus aureus infection and considered inactive against Gram-negative bacteria. We investigated the effectiveness of a daptomycin-meropenem combination by synergy kill curve and a pharmacokinetic/pharmacodynamic model. The combination may represent a novel therapeutic strategy against infections caused by KPC-producing K. pneumoniae strains.